BUILDING THE WORLD ONE BUILDING AT A TIME
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like a Lambo to me ! &3
SOLD POTN , BOUGHT AMPE, BOUGHT HEAVY AKER, BOUGHT HEAVY RLBD
these .023 / .024 are a steal, i will take all you want to give
Love this one, heading to $1.25 / 60 days i believe
WHALES IN THE BUILDING ON THE BUY SIDE $RLBD
Looking for great things here , STOP SIGN DOWN
$RLBD Financials Current and STOP SIGN DOWN , Also $POTN runner again
management is lean and buys no coffee and donuts, just on the search for the next good company. you believe or leave ! read the filings, COO and CEO have never sold a single share even when it went to .13 last year on very little shares! I believe something for real this time, we will see and it will be
send me the Fidelity post please
bidders in $RLBD
BIDDERS in , if you are going to short, you better get out now, bums
They would not spend money on financials if they did not have something coming
$RLBD , $POTN financials out and STOP sign coming down on $RLBD
This is another low floater , this guy found some really good picks so I just jumped in... I can see a double or triple tomorrow. $SRNE , $RLBD , $POTN
Yes great entry
We have 81,735,896 outstanding only 75,735,896 have been issued.. Please don't tell me they are adding these together... If so simply point out the word respectively , read carefully , there is no share scam , you must read every word .
Filings good 2,900,000 shares held back in by company of ex COO .
That being said , this one will have to move at some point up because it has no where to go but up now that the money borrowed has been paid back by open market selling already . Passing the warrant price
Market makers can definitely hold a stock down , we have witnessed them doing it first hand , putting ask orders in and no matter how many were in they kept filing below the ask on 2 1/2 million shares and kept it down on one we were buying before . But a year before that same stock went 10 fold on one tenth the volume . MM can do whatever they want to and blame it on keeping the market fair ....
This one on a role and quiet before the typhoon ....looking for RED OUT GREEN ON
This one looks like $5 to me , saw a European investment group getting involved as well
$RLBD , products hitting the streets in Florida , 2 nd round shipment hit Friday I heard
$RLBD and $POTN , nice big moves thru Feb we think
heard they are doing video review of stock movements, can't wait to see there opinion
AMPE good / AXER ready to go
Akers Biosciences, Inc. (NASDAQ: AKER) is a major developer in the health testing and screening products. Tests are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time. With numerous products now available to physicians this will speed up the diagnoses and plan of care time for each patient. $AKER GO GO GO UP UP UP
can you cover RLBD, I am in AKER also
see the article on them today
Updates coming I here holding tight to my shares
once that .035 is broken we head up from there
Holding here .....
better get it while you can , thats what i say
you saw BB haven post on RLBD , looks like push coming again this week
bought POTN on pullback and RLBD hearing news coming on big release
HOPEFULLY AKER AND SRNE , SEE THESE NUMBERS SOON
GOTTA LOVE THESE STORIES, ONE DAY : Big Drugmakers Pay Big Prices for Promising Biotechs -- Update
Print
Alert
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Intraday Stock Chart
Today : Monday 22 January 2018
Click Here for more JUNO THERAPEUTICS, INC. Charts.
By Jonathan D. Rockoff
Big drugmakers, searching for new sources of revenue, are paying hefty premiums for biotechnology businesses, with two multibillion-dollar acquisitions announced Monday among the latest such deals.
Sanofi SA agreed to pay $11.6 billion in cash, a 63% premium, to buy hemophilia-drug company Bioverativ Inc., confirming a Wall Street Journal report Sunday.
And Celgene's cash deal to buy Juno Therapeutics Inc. values shares in the biotech company at $9 billion, 87% more than their worth before the Journal reported on the deal talks last week.
So far this year, the median premium paid in health-care deals worth more than $1 billion is 89%, almost double the median of 45% since 2010, according to Dealogic.
Both Sanofi and Celgene have been looking to add products to cope with lower-price competition looming for their top-selling drugs.
As big drugmakers look to deal-making, rather than their own laboratories, to plug gaps in their product lineups, they are increasingly willing to pay up for the scarce roster of companies with promising products.
And analysts say premiums may only get bigger as other large drugmakers, aided by the new tax law in the U.S., consider acquisitions to bolster their lineups.
"Many of the largest, most cash-rich companies in the industry have not even begun to participate in M&A, and when they do, prices and deal volumes could step up significantly," Leerink Partners analyst Geoffrey Porges wrote Monday in a note to investors.
Paris-based Sanofi has already missed out on two high-valuation deals. It lost the bidding for Medivation to Pfizer Inc., which paid $14 billion for the cancer biotech company in 2016.
Then last year, Johnson & Johnson outbid Sanofi to buy rare-disease drugmaker Actelion for $30 billion.
Bioverativ, of Waltham, Mass., sells two top-selling treatments for the rare blood disorder hemophilia. The company was spun out of big biotech Biogen Inc. last year after Biogen couldn't find any companies willing to buy it for about $3 billion, according to a person familiar with the matter.
Sanofi turned to Bioverativ as low-price competition drew closer for the French company's top-selling product, Lantus insulin. Lantus revenue has been dropping but still accounted for 13% of Sanofi's sales during the first nine months of 2017.
Bioverativ's hemophilia drugs will fit in Sanofi's rare-disease business and complement the company's collaboration with biotech Alnylam Pharmaceuticals Inc. in developing a new kind of hemophilia therapy using an emerging technology called RNA interference.
Finally got filled shit , I was waiting waiting waiting , sent them shorts running .....
I have put in 5 buy orders trying to go over VDNM and all were cancelled , wow they must need to buy shares here
momentum looking incredible here up big